FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to pharmacology, and is applicable for producing a stabilising composition containing voriconazole. Stabilising a lyophilised composition is ensured by using lactose, wherein its amount required for the stabilisation process on a lactose monohydrate basis makes at least 3 weight fractions in relation to voriconazole. A method for stabilising the composition involves the stages of providing an aqueous solution containing voriconazole and hydroxypropyl-beta-cyclodextrine, adding at least 3 weight fractions of lactose, and lyophilising the produced composition. The stabilised composition for intravenous administration contains one weight fraction of voriconazole, 10-30 weight fractions of 2-hydroxypropyl-beta-cyclodextrine and at least 3 weight fractions of lactose on the lactose monohydrate basis.
EFFECT: using the inventions enables improving the stability of the lyophilised voriconazole compound.
9 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FORMULATIONS OF 2-IMINOBIOTINE AND USE THEREOF | 2011 |
|
RU2627460C2 |
| COMPOSITIONS WHICH CONTAIN EPOTHILONE, AND METHOD OF THEIR OBTAINING | 2005 |
|
RU2416407C2 |
| COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR, COMPOSITION OF RAS-FARNESYLT RANSFERASE INHIBITOR, PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2230062C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITIONS BASED ON 1,2-DIHYDROPYRIDINE COMPOUNDS | 2019 |
|
RU2824582C2 |
| AQUEOUS COMPOSITION CONTAINING DANTROLENE | 2016 |
|
RU2729043C2 |
| PARENTERAL LIQUID PREPARATION INCLUDING CARBAMATE COMPOUND | 2017 |
|
RU2761041C2 |
| BENDAMUSTINE AND CYCLOPOLYSACCHARIDE COMPOSITIONS | 2010 |
|
RU2734236C2 |
| COMPOSITIONS CONTAINING POLYSACCHARIDE MATRIX FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS | 2017 |
|
RU2748261C2 |
| INHALATION FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRIN AND CORTICOSTEROID | 2004 |
|
RU2390330C2 |
| COMPOSITIONS OF BENDAMUSTINE AND CYCLOPOLYSACCHARIDE | 2010 |
|
RU2591804C2 |
